A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine the safety, tolerability, and RP2D of BBI503 in combination with each of the selected anti-cancer agents.
Description
The purpose of this study is to evaluate the safety of the drug, BBI503, and what effects the drug has on cancer when it is given in combination with one of six standard anti-cancer drugs commonly used to treat advanced cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Advanced Cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
19 Apr 2024.
Study ID: 1510478761 (BBI503-201)
